W

West Tennessee Research Institute | Jackson, TN

Research site
(Unclaimed)
Location
369 North Parkway, Suite 400, Jackson, Tennessee, United States of America
Site insights

Top conditions

Arthritis (39 trials)

Rheumatoid Arthritis (27 trials)

Systemic Lupus Erythematosus (13 trials)

Psoriatic Arthritis (11 trials)

Sjogren's Syndrome (6 trials)

Top treatments

Methotrexate
Tofacitinib
Apremilast
Upadacitinib
Deucravacitinib
Secukinumab
Baricitinib
Adalimumab
Tocilizumab
SEL-212

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

19 of 68
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

The purpose of this study is to evaluate the safety and efficacy of risankizumab in adults with moderately to severely active psoriatic arthritis (Ps...

Active, not recruiting
Psoriatic Arthritis (PsA)
Biological: Risankizumab
Biological: Placebo

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Enrolling
Rheumatoid Arthritis
Drug: Baricitinib
Drug: TNF Inhibitor

The purpose of this study is to evaluate the efficacy and safety of deucravacitinib versus placebo in participants with active psoriatic arthritis wh...

Enrolling
Psoriatic Arthritis
Drug: Deucravacitinib
Other: Placebo

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Other: Placebo
Drug: Deucravacitinib

The primary objective of this study is to evaluate the long-term safety and tolerability of litifilimab in participants with active systemic lupus er...

Invitation-only
Systemic Lupus Erythematosus (SLE)
Drug: Litifilimab-matching placebo
Drug: Litifilimab

The purpose of this study is to assess the safety and efficacy of two doses of Deucravacitinib in adult participants with Active Sjögren's Syndrome.

Enrolling
Sjögren's Syndrome
Drug: Deucravacitinib
Other: Placebo

The primary objective of this study is to demonstrate efficacy of litifilimab (BIIB059) compared with placebo in participants with active systemic lu...

Enrolling
Lupus Erythematosus, Systemic
Drug: Litifilimab
Drug: Placebo

This study consists of two periods. The objective of Period 1 is to evaluate the efficacy of upadacitinib in combination with a 26-week corticosteroi...

Active, not recruiting
Giant Cell Arteritis (GCA)
Drug: Upadacitinib
Other: Placebo

The trial will evaluate efficacy, safety and tolerability of ianalumab compared to placebo, given as monthly subcutaneous (s.c.) injection on top of...

Enrolling
Systemic Lupus Erythematosus
Drug: placebo
Drug: ianalumab
Locations recently updated

This is a phase III study of efficacy and safety of secukinumab versus placebo, in combination with glucocorticoid taper regimen, in patients with gi...

Enrolling
Giant Cell Arteritis (GCA)
Biological: Secukinumab 150 mg
Other: Placebo
Locations recently updated

The purpose of this study is to demonstrate the efficacy and safety of secukinumab 300 milligram (mg) and 150 mg administered subcutaneously (s.c.) f...

Enrolling
Polymyalgia Rheumatica
Drug: Secukinumab 150 mg
Drug: Secukinumab 300 mg

Systemic Lupus Erythematosus (SLE) is an immune-mediated disease associated with inflammation of multiple organ systems. This study will assess how s...

Enrolling
Systemic Lupus Erythematosus
Drug: Upadacitinib
Drug: Placebo

The purpose of this study is to assess long term safety in participants who have completed a Novartis trial with secukinumab, have been judged by the...

Enrolling
Autoimmunity, Inflammation
Biological: Secukinumab s.c. injection
Locations recently updated

The purpose of the present study is to assess the efficacy of secukinumab 300 mg s.c. (subcutaneous) compared to placebo, each in combination with st...

Enrolling
Rotator Cuff Tendinopathy
Drug: Secukinumab
Drug: Placebo

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. This study will assess how...

Enrolling
Rheumatoid Arthritis
Drug: Adalimumab
Drug: Upadacitinib

Phase 2 study of the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KPL-404 in subjects with moderate to severe R...

Active, not recruiting
Arthritis, Rheumatoid
Drug: Placebo
Drug: KPL-404

This study will examine how intravenous (i.v.) Secukinumab will be processed in the body (pharmacokinetics [PK]) and whether it will be safe and tole...

Enrolling
Polymyalgia Rheumatica
Giant Cell Arteritis
Drug: Secukinumab
Locations recently updated

A randomized, double-blind, placebo controlled, 3-arm multicenter phase 3 study to assess the efficacy and safety of ianalumab in patients with activ...

Enrolling
Sjogren Syndrome
Biological: VAY736
Other: Placebo

The RESET-RA study will assess the safety and efficacy of the SetPoint System (study device) for the treatment of adult patients with active, moderat...

Active, not recruiting
Rheumatoid Arthritis
Procedure: Implant Procedure
Drug: Conventional Synthetic DMARD

Trial sponsors

Pfizer logo

Pfizer (13 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems